Intec Pharma Ltd.
10 Hartom Street (Rmpe Building)
68 articles with Intec Pharma Ltd.
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
Pursuing medical cannabinoids for a variety of pain indications
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma, has issued a Letter to Shareholders, the full text of which follows below.
Accordion Pill for proprietary compound achieves in-vitro specifications
Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019
Intec Pharma Ltd. today announces that Company management will participate at the following upcoming investment conferences in November.
Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society
Intec Pharma Ltd. today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson's and Movement Disorder Society (MDS 2018) being held from October 5-9, 2018 in Hong Kong.
Intec Pharma Ltd. today announces that Company management will participate at the following upcoming investment conferences.
Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study
Former LabCorp CFO Brings Wealth of Financial Experience
Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City.
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces financial results for the three months ended March 31, 2018 and provides a corporate update.
Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at the American Academy of Neurology 2018 Annual Meeting (AAN 2018) underway in Los Angeles
Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share.
Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease
Intec Pharma Ltd [http://intecpharma.com ]. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill(TM) [http://intecpharma.com/technology ] platform technology, today announced it will host a Key Opinion Leader (KOL) luncheon on the topic of Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease on Wednesday, April 11 (World Parkinson's Day), in New York City.
More than 300 patients enrolled in pivotal Phase 3 ACCORDANCE Trial Gastroscopy safety sub-study successfully completed.
Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill(TM) platform technology, today announced that the Company's officers will provide a corporate overview at four investor presentations in March 2018.
Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.
Intec Pharma today announced it has entered into a Feasibility and Option agreement with Novartis Pharma to explore using the Accordion Pill platform for a proprietary Novartis compound.
Intec Pharma today announced that the Canadian Intellectual Property Office has issued a Certificate of Grant of a Canadian patent No. 2,721,493.
Intec Pharma today announced its third quarter 2017 financial results and provided a corporate update.